Navigation Links
Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Date:11/6/2007

In Phase I Clinical Evaluation Anticoagulant Inhibits Clotting Factor IXa;

Matched Antidote Rapidly Reverses Anticoagulant Effect

ORLANDO, Fla., Nov. 6 /PRNewswire/ -- Regado Biosciences today presented encouraging data from Phase Ia and Phase Ib dose escalation studies of the Company's REG1 Anticoagulation System. REG1 is a two-component system consisting of an aptamer-based anticoagulant, RB006, and its matched antidote, RB007, which binds to and neutralizes RB006. The data showed RB006 completely inhibited the activity of Factor IXa, a protein essential to blood clotting, and RB006's activity was rapidly and safely reversed by RB007 in the Phase I studies. Confirming previously reported Phase I results, these data were presented at the American Heart Association's 2007 Scientific Sessions, currently being held in Orlando, Florida.

"These Phase I results are encouraging, and this system should be evaluated further in confirmatory Phase II and III clinical studies. Experienced clinicians recognize the importance of being able to titrate the intensity of anticoagulation according to specific patient needs. Current drugs do not offer an optimal level of control or flexibility," said Richard C. Becker, M.D., Professor of Medicine, Duke University Medical Center, and Director, Duke Cardiovascular Thrombosis Center, Duke Clinical Research Institute. "Should additional well-controlled clinical studies confirm these data, REG1 may have potential for broad applications in clinical practice settings from the emergency room to the operating room."

Scientists from the Duke Clinical Research Institute and Regado analyzed REG1 pharmacokinetics and dosing data from 134 subjects enrolled in two of the three Phase I studies. The Phase Ia study enrolled 84 healthy volunteers; the Phase Ib study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results of the analysis showed an int
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/24/2014)... 23, 2014  Medical Science Liaisons play a large ... between the medical device industry and key stakeholders, the ... coming years as the device industry relies on them ... research by benchmarking firm, Best Practices, LLC, one area ... edge is by harnessing new technology to enable education. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
(Date:12/24/2014)... Over 700 toys, that’s what ... That is 700 smiling little faces this holiday that ... $6000 in monetary donations was given to the various ... expenses they incur through the year. Some of the ... Child's Haven , Shrine's Children's Hospitals, Toys for Tots ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... 25, 2014 Today, UWDress.com, the famous women’s ... wedding gowns, and launched a site-wide wedding gown promotion. ... wedding gowns in a more unexpected way, the collection should ... popular in the global market, and they are available with ... are offered at discounted prices, up to 75% off; most ...
(Date:12/24/2014)... BambooIndustry.com a famous bamboo flooring company offering bamboo flooring ... announces its multiple layer bamboo panel board collection , ... , Bamboo panel is the product made from 100 ... board features high quality selective bamboo and eco-friendly adhesives ... panel consists of multiple layers of bamboo. , According ...
(Date:12/24/2014)... A new, injectable weight-loss drug has been approved by ... on Tuesday approved Saxenda (liraglutide) for adults who are ... at least one weight-related health condition, such as high ... Patients taking the drug, made by Novo Nordisk, should ... FDA noted. "Obesity is a public health concern ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3
... Negative pressure wound therapy is a new innovation in treating ... for frequent and stressful dressing changes. A new study ... a wide range of applications with children, and can be ... a vacuum system which applies negative suction pressure to the ...
... Bereaved families of firefighters who lost their lives to work- ... relief at last. Ontarios new labor laws state that they ... in order to qualify for compensation due the dead workers ... identify eight types of cancer that will be presumed to ...
... Service, an agency of the New York state government has ... County Hospital as a shameful "chamber of filth, decay, ... Civil Liberties Union, the agency has filed a suit in ... the ward, where patients are subjected to overcrowded conditions, physical ...
... is recalling half-gallon packages of Galliker's Acidophilus Plus Reduced ... milk may be unsafe. It has not been shown ... the raw milk itself to determine the presence or ... is free of infectious organisms. Only products with the ...
... An oral vaccine can prevent mice from developing a brain ... will be presented at the American Academy of Neurology's ... 2007. Prion diseases, which include scrapie, mad cow disease, and ... or cure. ,The disease spreads when an animal ...
... Coast Eagles star Ben Cousins broke his silence for the first ... that he has indeed a problem of substance abuse. ... rehabilitation centre for the past months. He was being treated for ... ,He did not disclose the name of the drug ...
Cached Medicine News:Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 2Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 3Health News:Suit Filed Against Horrors of Psychiatric Ward in New York Hospital 2Health News:Vaccine Prevents Prion Disease in Mice 2Health News:Cousins Recovering from His Substance Abuse Problem 2
... CellTracks® Analyzer II is ... used to enumerate fluorescently ... immunomagnetically selected and aligned. ... the CellTracks® Analyzer II, ...
... These unique Acid Fast ... sputum smear with appropriate background ... containing a positive and negative ... Kinyoun (Cat. No. 353), Ziehl-Neelsen ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Medicine Products: